Biogen Inc. (IDP)
XDUS
Delayed Data
Oct 19, 2026, 06:00 AM
Day's Range
206.8552 wk Range
122.00Overview - IDP - Biogen Inc.
Key Statistics
Valuation
P/E (Trailing)
‪23.81‬
PEG Ratio
‪-0.28‬
Price / Book
‪1.64‬
Profitability
Gross Margin
‪71.60%‬
Profit Margin
‪75.69%‬
Operating Margin
‪18.44%‬
Return on Assets
‪4.39%‬
Return on Equity
‪7.08%‬
Ownership
Shares Outstanding
147.70M
Price stats
50-Day Avg
‪188.46‬
200-Day Avg
‪169.61‬
Peers - IDP - Biogen Inc.
Peer Comparison
Compared with companies in Drug Manufacturers - General listed on XDUS.
- IDPXDUSBiogen Inc.+40.40%52-week change23.81P/E (Trailing)‪75.69%‬Profit Margin
- 6MKXDUSMerck & Co., Inc.+43.34%52-week change17.66P/E (Trailing)‪74.80%‬Profit Margin
- BAYAXDUSBayer AG Sponsored ADR+38.89%52-week change-11.74P/E (Trailing)‪58.75%‬Profit Margin
- BAYNXDUSBayer AG+38.13%52-week change-12.00P/E (Trailing)‪58.75%‬Profit Margin
- AMGXDUSAmgen Inc.+32.95%52-week change26.92P/E (Trailing)‪67.24%‬Profit Margin
- 7XPXDUSOrganon & Co.+31.68%52-week change17.05P/E (Trailing)‪53.29%‬Profit Margin
- BRMXDUSBristol-Myers Squibb Company+31.19%52-week change16.07P/E (Trailing)‪71.08%‬Profit Margin
Profile Summary - IDP - Biogen Inc.
About
Biogen Inc. is a biotechnology company focused on discovering, developing, and delivering therapies for serious neurological, neurodegenerative, and rare diseases. Biogen’s current portfolio includes treatments for multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis, and…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
